ical genomics research, ChemGenex recently initiated Phase I/II human clinical trials with Ceflatonin as a potential treatment for patients with acute promyelocytic leukemia (APL). Ceflatonin is a natural product compound with demonstrated clinical activity as a single agent in hematological malignancies and research suggests other therapeutic uses for Ceflatonin in lymphoma and as a chemopotentiator in solid tumors. The research reported by ChemGenex today demonstrates that Ceflatonin affects specific genes and cellular pathways both in vitro and in vivo, including genes known to play a role in leukemia and key cellular transcription factors that are up-regulated in many solid tumors.
Ceflatonin Effect on Gene Expression Studied both In Vitro and In Vivo
In the research presented today, the ChemGenex scientists used a high-density array system to analyze the effects of Ceflatonin on gene expression within a human colon cancer cell line in vitro and on tumor growth and gene expression in fibrosarcoma cells grown in mice.
The researchers reported both up- and down-regulation of a number of genes in vitro, including effects on genes from the histone family and transcription factor Jun. Histone proteins are an integral part of the structure of chromosomes, and modified forms of these proteins are understood to play a role in leukemia. Jun is an important transcription factor that is regulated in response to a variety of growth factors, and up-regulation of this gene is associated with many solid tumors. Studies of gene expression in response to Ceflatonin in vivo demonstrated up-regulation of a variety of genes with transportation function as well as some unknown genes.
Understanding the patterns of gene expression in response to Ceflatonin, both in vitro and in vivo, helps us to advance the development of this drug in multiple ways, said Anil Sehgal, Ph.D. director of molecular biology and genomics at ChemGenex. First, the patternsPage: 1 2 3 Related biology news :1
Contact: Joan Kureczka
. International symposium on nutritional genomics2
. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics3
. Full promise of genomics in disease research yet to be realized4
. Pharmacogenomics could replace trial-and-error with science from the human genome5
. Dartmouth Medical School awarded $9 million grant for genomics research6
. Functional genomics enables easy target identification and drives drug discovery7
. Library on a Slide: Whole genome microarrays for comparative genomics8
. New genomics tool boosts diabetes research9
. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology10
. Emerging frontiers genomics grant for blue-green bacteria11
. What can the genomics revolution teach us about global change?